


Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
Esomeprazole (esomeprazole, Nexium), developed and manufactured by AstraZeneca in the UK, is a prescription drug.
It was first launched in the UK in 2000 and then in the United States in 2001. In 2003, esomeprazole (esomeprazole, Nexium) was marketed in China and included in the national medical insurance reimbursement program.
1. Healing of erosive esophagitis (EE).
2. Maintenance after EE healing.
3. Treatment of symptomatic gastroesophageal reflux disease (GERD).
4. Reduction of the risk of non-steroidal anti-inflammatory drug (NSAID)-associated gastric ulcers.
5. Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence.
6. Pathological hypersecretory diseases, including Zollinger-Ellison syndrome.
1. The recommended maximum daily dose for patients with severe hepatic impairment (Child-Pugh Class C) is 20 mg once daily.
2. Most patients heal within 4 to 8 weeks. For patients who have not healed after 4 to 8 weeks, an additional 4 to 8 weeks of treatment may be required to achieve healing.
3. For dosage adjustments in elderly patients and those with renal impairment, refer to the prescribing information for amoxicillin and clarithromycin.
4. The recommended starting dose for patients with severe hepatic impairment (Child-Pugh Class C) is 20 mg twice daily.
